The short version of TB-500 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-16 and is reviewed periodically as new material appears.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
=== Elimination === Bicalutamide is eliminated in feces (43%) and urine (34%), whereas its metabolites are eliminated in approximately equal proportions in urine and bile. It is excreted to a substantial extent in its unmetabolized form, with both bicalutamide and its metabolites excreted mainly as glucuronide conjugates.
Ionization of acids is less in an acidic solvent than in water. For example, hydrogen chloride is a weak acid when dissolved in acetic acid. This is because acetic acid is a much weaker base than water.
The subject is required to touch his or her nose with eyes closed; people with normal proprioception may make an error of no more than 20 mm (0.79 in), while people with impaired proprioception (a symptom of moderate to severe alcohol intoxication) fail this test due to difficulty locating their limbs in space relative to their noses.
== Industrial uses == Penicillium digitatum is used as a biological tool during the commercial production of latex agglutination kits. Latex agglutination detects Aspergillus and Penicillium species in foods by attaching antibodies specific for the extracellular polysaccharide of P. digitatum to 0.8 μm latex beads. This method has been successful in detecting contamination of grains and processed foods at a limit of detection of 5–10 ng/mL of antigen. In comparison to other detection assays, the latex agglutination assay exceeds the detection limit of the Enzyme-linked immunosorbent assay (ELISA) and is as effective in detecting Aspergillus and Pencillium species as the ergosterol production assay. However, the latter displays an increased ability to detect Fusarium species, when compared to the latex agglutination assay.
Sources: en.wikipedia.org
==== Transconjunctival lower blepharoplasty ==== Transconjunctival blepharoplasty is performed through an incision on the inner surface of the lower eyelid. This technique allows for removal or repositioning of orbital fat without an external scar and is commonly used in patients with minimal or no excess skin. Because skin is not removed, additional procedures may be required if skin laxity is present.
Diphenhydramine, while traditionally known as an antagonist, acts primarily as an inverse agonist of the histamine H1 receptor. It is a member of the ethanolamine class of antihistaminergic agents. By reversing the effects of histamine on the capillaries, it can reduce the intensity of allergic symptoms. It also crosses the blood–brain barrier and inversely agonizes the H1 receptors centrally. Its effects on central H1 receptors cause drowsiness. Diphenhydramine is a potent antimuscarinic (a competitive antagonist of muscarinic acetylcholine receptors) and, as such, at high doses can cause anticholinergic syndrome. The utility of diphenhydramine as an antiparkinson agent is the result of its blocking properties on the muscarinic acetylcholine receptors in the brain. Diphenhydramine also acts as an intracellular sodium channel blocker, which is responsible for its actions as a local anesthetic. Diphenhydramine has also been shown to inhibit the reuptake of serotonin. It has been shown to be a potentiator of analgesia induced by morphine, but not by endogenous opioids, in rats. The drug has also been found to act as an inhibitor of histamine N-methyltransferase (HNMT).
7 November Senior U.S. commanders in South Vietnam said that all ground combat forces could be pulled out by mid-1971. Five VC platoons numbering some 200 men attacked Saigon's District 7 but were repulsed by National Police. The PAVN attacked an ARVN riverine base 138 miles (222 km) southwest of Saigon killing 25 defenders.
Sources: en.wikipedia.org
According to the online portal Box Office Mojo and the review aggregate site Rotten Tomatoes, DiCaprio's most critically and commercially successful films include What's Eating Gilbert Grape (1993), Romeo + Juliet (1996), Titanic (1997), Catch Me If You Can (2002), Gangs of New York (2002), The Aviator (2004), The Departed (2006), Blood Diamond (2006), Revolutionary Road (2008), Shutter Island (2010), Inception (2010), Django Unchained (2012), The Great Gatsby (2013), The Wolf of Wall Street (2013), The Revenant (2015), Once Upon a Time in Hollywood (2019), Don't Look Up (2021), Killers of the Flower Moon (2023), and One Battle After Another (2025). His films have grossed $7.2 billion worldwide. DiCaprio has been recognized with seven nominations, including one win, by the Academy of Motion Picture Arts and Sciences for the following:
=== Dentition === Komodo dragons have ziphodont teeth, which are defined as teeth that are laterally flattened, recurved, and with serrated tooth crowns where the serrations have a dentine core and a very thin enamel outer layer. This is the same type of dentition observed in many extinct theropod dinosaurs. The teeth of the insectivorous juveniles in contrast are barely recurved, with fewer and less well-developed serrations that lack dentine cores.
UTC Climate, Controls & Security was a global provider of building technologies offering fire safety, security, building automation, heating, ventilating, air-conditioning, and refrigeration systems and services. A wholly owned subsidiary of United Technologies Corporation, UTC Climate, Controls & Security was a $16.7 billion company with 55,000 employees serving customers in more than 180 countries. In 2020, United Technologies spun off this subsidiary into the independent Carrier Global Corporation. At the same time United Technologies spun off Otis Worldwide Corporation, and then the remaining United Technologies units (Pratt & Whitney and Collins Aerospace) merged with the Raytheon Company to create Raytheon Technologies.
=== Switzerland === The Swiss government agreed to contribute to the security costs borne by the cantons of Geneva, Vaud and Valais. The Swiss Armed Forces were authorised to deploy up to 5,000 personnel in support of the cantonal authorities. In Geneva, approximately 7,400 police officers, soldiers and customs personnel were mobilised for the summit period. The canton of Geneva estimated the security cost at around 20 million Swiss francs, while a fund of 6 million Swiss francs was created to support businesses affected by possible unrest or security restrictions. Switzerland and France also approved a joint military cooperation framework for the summit, setting out procedures for coordination between the Swiss Federal Department of Defence, Civil Protection and Sport and the French Ministry of the Armed Forces. The summit led to the cancellation of public 2026 FIFA World Cup fan zones in Geneva and Lausanne.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.